SCHEMBL7177976

SCHEMBL7177976

CC[C@]12CC[C@@H]3c4ccc(OS(N)(=O)=O)cc4CC[C@H]3[C@@H]1CCC2=O

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STS P08842 17/20 0.74
CA1 P00915 2/20 0.74
CA2 P00918 2/20 0.74
CA9 Q16790 2/20 0.74
ESR1 P03372 1/20 0.74
CA4 P22748 1/20 0.74
CA6 P23280 1/20 0.74
ESR2 Q92731 1/20 0.74
HSD17B1 P14061 2/20 0.60
ABCC4 O15439 1/20 0.60
CYP2C9 P11712 1/20 0.60
ABCC1 P33527 1/20 0.60
SLCO1B1 Q9Y6L6 1/20 0.60
KDM4E B2RXH2 1/20 0.60
LMNA P02545 1/20 0.56
MAPT P10636 1/20 0.56
RECQL P46063 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11857389 0.88 LMNA (0.72) STSCA1CA2CA9ESR1
SCHEMBL11862021 0.88 LMNA (0.72) STSCA1CA2CA9ESR1
SCHEMBL11857394 0.88 LMNA (0.72) STSCA1CA2CA9ESR1
SCHEMBL28068491 0.88 LMNA (0.72) STSCA1CA2CA9ESR1
SCHEMBL4623091 0.88 LMNA (0.72) STSCA1CA2CA9ESR1
Emate SCHEMBL6370815 0.85 STS (1.00) STSCA1CA2CA9ESR1
Emate SCHEMBL14548146 0.85 STS (1.00) STSCA1CA2CA9ESR1
Emate SCHEMBL305660 0.85 STS (1.00) STSCA1CA2CA9ESR1
Emate SCHEMBL10062721 0.85 STS (1.00) STSCA1CA2CA9ESR1
Emate SCHEMBL29406834 0.85 STS (1.00) STSCA1CA2CA9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US disclosed